NCT01922284 - Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

December 31, 2015

Conditions

HIV

Interventions

BIOLOGICAL

DNA

8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54

BIOLOGICAL

MVA-C

1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54

BIOLOGICAL

CN54rgp140

100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54

BIOLOGICAL

GLA-AF

5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant

Trial Locations (2)

GU2 7XP

Surrey Clinical Research Centre, University of Surrey, Guildford

W2 1PG

Imperial College London, Greater London